A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
P Coto-Segura, C Segú-Vergés, A Martorell… - Frontiers in …, 2023 - frontiersin.org
Background Psoriasis is a chronic immune-mediated inflammatory systemic disease with
skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques …
skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques …
[HTML][HTML] Clinical considerations in the management of hidradenitis suppurativa in women
Hidradenitis suppurativa (HS) is a chronic, inflammatory disease of the skin with a
predilection for women. The role of sex hormones, including estrogen and progesterone, is …
predilection for women. The role of sex hormones, including estrogen and progesterone, is …
A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy
The inflammatory bowel diseases commonly affect individuals during their peak
reproductive years. Patients are often concerned about the impact of medical therapies on …
reproductive years. Patients are often concerned about the impact of medical therapies on …
[HTML][HTML] The psoriasis decision tree
G Monks, R Rivera-Oyola… - The Journal of Clinical and …, 2021 - ncbi.nlm.nih.gov
Psoriasis, an inflammatory disorder of the skin, is associated with an increased risk of
systemic diseases, such as psoriatic arthritis, psychiatric disorders, malignancy, and …
systemic diseases, such as psoriatic arthritis, psychiatric disorders, malignancy, and …
Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper
J Yeung, MJ Gooderham, P Grewal… - Journal of …, 2020 - journals.sagepub.com
Background Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at
peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of …
peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of …
Psoriasis. diagnostic and therapeutic recommendations of the polish dermatological society. part 2
A Reich, Z Adamski, G Chodorowska… - Dermatology Review …, 2020 - termedia.pl
Psoriasis is one of the most common chronic inflammatory dermatoses. We present the
second part of the diagnostic and therapeutic guidelines on psoriasis. The second part …
second part of the diagnostic and therapeutic guidelines on psoriasis. The second part …
TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: Therapeutic utility in the era of IL-17 and IL-23 inhibitors
JJ Hong, EK Hadeler, ML Mosca… - Journal of psoriasis …, 2022 - journals.sagepub.com
Psoriasis is a chronic inflammatory condition for which eleven FDA-approved biologic
therapies are approved. Over the past decade, studies have documented the higher efficacy …
therapies are approved. Over the past decade, studies have documented the higher efficacy …
Opportunities and challenges for PBPK model of mAbs in paediatrics and pregnancy
KL Gill, HM Jones - The AAPS Journal, 2022 - Springer
New drugs may in some cases need to be tested in paediatric and pregnant patients.
However, it is difficult to recruit such patients and there are many ethical issues around their …
However, it is difficult to recruit such patients and there are many ethical issues around their …
Rheumatology-led pregnancy clinic: enhancing the care of women with rheumatic diseases during pregnancy
Y El Miedany, D Palmer - Clinical Rheumatology, 2020 - Springer
The autoimmune rheumatic diseases have a clear predilection for women. Consequently,
issues regarding family planning and pregnancy are a vital component of the management …
issues regarding family planning and pregnancy are a vital component of the management …
GRAPPA debate: targeted small molecules versus biologics as first-line systemic therapy after conventional therapy for moderate-to-severe psoriasis
In this debate at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) 2023 annual meeting, arguments were made contrasting the first-line use of oral …
(GRAPPA) 2023 annual meeting, arguments were made contrasting the first-line use of oral …